Inhibrx Biosciences (INBX) Non Operating Income (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Non Operating Income data on file, last reported at -$1.9 million in Q4 2025.

• On a quarterly basis, Non Operating Income fell 192.63% year-over-year to -$1.9 million in Q4 2025; TTM through Dec 2025 was -$5.0 million, a 100.25% decrease from a year earlier, with the FY2025 full-year figure at -$5.0 million, down 100.25% from the prior year.
• Non Operating Income for Q4 2025 stood at -$1.9 million, down from -$1.4 million in the prior quarter.
• Over the last five years, Non Operating Income for INBX reached as high as $2.0 billion in Q2 2024 and fell as low as -$6.0 million in Q3 2023.
• Historically, Non Operating Income has averaged $181.7 million across 3 years, with a median of -$1.4 million in 2025.
• Across the five-year window, Non Operating Income soared 35469.85% in 2024 and slumped 192.63% in 2025, its largest moves.
• Year by year, Non Operating Income stood at -$3.7 million in 2023, then surged by 155.98% to $2.1 million in 2024, then plunged by 192.63% to -$1.9 million in 2025.
• Per Business Quant data, the three most recent Non Operating Income figures were -$1.9 million in Q4 2025, -$1.4 million in Q3 2025, and -$1.3 million in Q2 2025.